id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2021-N-0851-0053,FDA,FDA-2021-N-0851,Medical Devices; Immunology and Microbiology Devices; Classification of the Human Leukocyte Antigen Typing Companion Diagnostic Test,Rule,Final Rule,2022-12-27T05:00:00Z,2022,12,2022-12-27T05:00:00Z,,2022-12-27T17:54:52Z,2022-28035,0,0,0900006485558187
FDA-2021-N-0851-0002,FDA,FDA-2021-N-0851,"Medical Devices; Immunology and Microbiology Devices; Classification of Human Leukocyte, Neutrophil and Platelet Antigen and Antibody Tests: Preliminary Regulatory Impact Analysis",Other,Additional Information,2022-01-21T05:00:00Z,2022,1,2022-01-21T05:00:00Z,,2022-01-21T18:00:33Z,,0,0,0900006484f2e031
FDA-2021-N-0851-0001,FDA,FDA-2021-N-0851,"Medical Devices; Immunology and Microbiology Devices; Classification of Human Leukocyte, Neutrophil and Platelet Antigen and Antibody Tests",Proposed Rule,Notice of Proposed Rulemaking (NPRM),2022-01-21T05:00:00Z,2022,1,2022-01-21T05:00:00Z,2022-04-22T03:59:59Z,2022-12-27T17:58:44Z,2022-01156,0,0,0900006484f2ce84